WHY IT MATTERS: If you or a loved one is living with Alzheimer’s-related agitation, the expansion of this clinical trial means more opportunities to access investigational cannabinoid therapy and brings us closer to having FDA-reviewed evidence for cannabis-based treatment options in dementia care. CLINICAL OVERVIEW: The expansion of clinical trial sites for IGC Pharma’s Phase 2 CALMA trial investigating cannabinoid-based therapy for Alzheimer’s-associated agitation represents a meaningful step in building the evidence base for cannabis medicine in neurodegenerative disease. Alzheimer’s-related behavioral symptoms like agitation and aggression are notoriously difficult to manage with conventional medications, and cannabinoid therapies have shown early promise in addressing neuroinflammation and behavioral dysregulation through endocannabinoid system modulation.
Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study
Parkinson disease (PD) is a neurodegenerative disorder very common among the older population. Since standard treatments often only partially relieve symptoms, many patients turn to complementary and alternative medication such as cannabis....
Tetrahydrocannabinol-Rich Extracts From Cannabis Sativa L. Improve Glucose Consumption and Modulate Metabolic Complications Linked to Neurodegenerativ
Tetrahydrocannabinol (THC), a major constituent of the plant cannabis, can interact with endocannabinoid receptors abundant on neurons, thereby affecting multiple neuronal processes. In particular, a group of scientists recently investigated the ability...